Lv71
5000 积分 2023-01-09 加入
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
4天前
已完结
Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo
7天前
已完结
Update on the Development of MNK Inhibitors as Therapeutic Agents
18天前
已完结
Update on the Development of MNK Inhibitors as Therapeutic Agents
20天前
已完结
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
20天前
已完结
Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition
21天前
已完结
MNK1 and MNK2 Expression in the Human Dorsal Root and Trigeminal Ganglion
29天前
已完结
Resistance to antibody–drug conjugates: A review
1个月前
已完结
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
1个月前
已完结
Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain
1个月前
已完结
皖公网安备34019202002308
